Tumor-induced MDSC act via remote control to inhibit L-selectin-dependent adaptive immunity in lymph nodes

eLife

Volumn 5, Issue DECEMBER2016, 2016, Pages

  Ku, Amy W ^a   Muhitch, Jason B ^a   Powers, Colin A ^a   Diehl, Michael ^a   Kim, Minhyung ^a   Fisher, Daniel T ^a   Sharda, Anand P ^a   Clements, Virginia K ^b   O’Loughlin, Kieran ^a   Minderman, Hans ^a   Messmer, Michelle N ^a   Ma, Jing ^c   Skitzki, Joseph J ^a   Steeber, Douglas A ^d   Walcheck, Bruce ^c   Ostrand Rosenberg, Suzanne ^b   Abrams, Scott I ^a   Evans, Sharon S ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b UNIVERSITY OF MARYLAND BALTIMORE COUNTY   (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

^d UNIVERSITY OF WISCONSIN MILWAUKEE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD11B ANTIGEN; GAMMA INTERFERON; L SELECTIN;

ADAPTIVE IMMUNITY; ADOPTIVE TRANSFER; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL ADHESION; CHEMOTAXIS ASSAY; CONTROLLED STUDY; CYTOFLUOROMETRY; ENZYME LINKED IMMUNOSORBENT ASSAY; EXTRAVASATION; FLOW CYTOMETRY; HISTOLOGY; HYPERTHERMIA; IMMUNOFLUORESCENCE; INTRAVITAL MICROSCOPY; LYMPH NODE; MOUSE; MYELOID DERIVED SUPPRESSOR CELL; NONHUMAN; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SPLENECTOMY; SUPPRESSOR CELL; TUMOR VOLUME; ANIMAL; BAGG ALBINO MOUSE; BIOSYNTHESIS; C57BL MOUSE; DISEASE MODEL; FEMALE; GENE EXPRESSION REGULATION; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; LYMPHOCYTE; MALE; METABOLISM; MYELOID-DERIVED SUPPRESSOR CELL; NEOPLASM; PATHOPHYSIOLOGY; PHYSIOLOGY; RNA INTERFERENCE; TRANSGENIC MOUSE; TUMOR CELL LINE; XENOGRAFT;

ADAPTIVE IMMUNITY; ANIMALS; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; IMMUNE TOLERANCE; L-SELECTIN; LYMPH NODES; LYMPHOCYTES; MALE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, TRANSGENIC; MYELOID-DERIVED SUPPRESSOR CELLS; NEOPLASMS; RNA INTERFERENCE; TRANSPLANTATION, HETEROLOGOUS;

EID: 85008439825     PISSN: None     EISSN: 2050084X     Source Type: Journal    
DOI: 10.7554/eLife.17375.001     Document Type: Article

References (84)

1. Abramoff MD, Magelhaes PJ, Ram SJ. 2004. Image processing with ImageJ. Biophotonics International 11:36-42.
2. Acharyya S, Oskarsson T, Vanharanta S, Malladi S, Kim J, Morris PG, Manova-Todorova K, Leversha M, Hogg N, Seshan VE, Norton L, Brogi E, Massagué J. 2012. A CXCL1 paracrine network links cancer chemoresistance and metastasis. Cell 150:165-178. doi: 10.1016/j.cell.2012.04.042
3. Alexander JP, Kudoh S, Melsop KA, Hamilton TA, Edinger MG, Tubbs RR, Sica D, Tuason L, Klein E, Bukowski RM. 1993. T-cells infiltrating renal cell carcinoma display a poor proliferative response even though they can produce interleukin 2 and express interleukin 2 receptors. Cancer Research 53:1380-1387
4. Aliper AM, Frieden-Korovkina VP, Buzdin A, Roumiantsev SA, Zhavoronkov A. 2014. Interactome analysis of myeloid-derived suppressor cells in murine models of colon and breast cancer. Oncotarget 5:11345-11353. doi: 10.18632/oncotarget.2489
5. Alizadeh D, Trad M, Hanke NT, Larmonier CB, Janikashvili N, Bonnotte B, Katsanis E, Larmonier N. 2014. Doxorubicin eliminates myeloid-derived suppressor cells and enhances the efficacy of adoptive T-cell transfer in breast cancer. Cancer Research 74:104-118. doi: 10.1158/0008-5472.CAN-13-1545
6. Beury DW, Parker KH, Nyandjo M, Sinha P, Carter KA, Ostrand-Rosenberg S. 2014. Cross-talk among myeloid-derived suppressor cells, macrophages, and tumor cells impacts the inflammatory milieu of solid tumors. Journal of Leukocyte Biology 96:1109-1118. doi: 10.1189/jlb.3A0414-210R
7. Bodogai M, Moritoh K, Lee-Chang C, Hollander CM, Sherman-Baust CA, Wersto RP, Araki Y, Miyoshi I, Yang L, Trinchieri G, Biragyn A. 2015. Immunosuppressive and prometastatic functions of Myeloid-Derived suppressive cells rely upon education from Tumor-Associated B cells. Cancer Research 75:3456-3465. doi: 10.1158/0008-5472.CAN-14-3077
8. Body-Malapel M, Dharancy S, Berrebi D, Louvet A, Hugot JP, Philpott DJ, Giovannini M, Chareyre F, Pages G, Gantier E, Girardin SE, Garcia I, Hudault S, Conti F, Sansonetti PJ, Chamaillard M, Desreumaux P, Dubuquoy L, Mathurin P. 2008. NOD2: a potential target for regulating liver injury. Laboratory Investigation 88 318-327 doi: 10.1038/labinvest.3700716
9. Bracci L, Schiavoni G, Sistigu A, Belardelli F. 2014. Immune-based mechanisms of cytotoxic chemotherapy: implications for the design of novel and rationale-based combined treatments against cancer. Cell Death and Differentiation 21:15-25. doi: 10.1038/cdd.2013.67
10. Chen D, Xia J, Tanaka Y, Chen H, Koido S, Wernet O, Mukherjee P, Gendler SJ, Kufe D, Gong J. 2003. Immunotherapy of spontaneous mammary carcinoma with fusions of dendritic cells and mucin 1-positive carcinoma cells. Immunology 109:300-307. doi: 10.1046/j.1365-2567.2003.01656.x
11. Chen Q, Fisher DT, Clancy KA, Gauguet JM, Wang WC, Unger E, Rose-John S, von Andrian UH, Baumann H, Evans SS. 2006. Fever-range thermal stress promotes lymphocyte trafficking across high endothelial venules via an interleukin 6 trans-signaling mechanism. Nature Immunology 7:1299-1308. doi: 10.1038/ni1406
12. Choudhary D, Hegde P, Voznesensky O, Choudhary S, Kopsiaftis S, Claffey KP, Pilbeam CC, Taylor JA. 2015. Increased expression of L-selectin (CD62L) in high-grade urothelial carcinoma: A potential marker for metastatic disease. Urologic Oncology: Seminars and Original Investigations 33387:387.e17-387387. doi: 10.1016/j.urolonc.2014.12.009
13. Cortez-Retamozo V, Etzrodt M, Newton A, Rauch PJ, Chudnovskiy A, Berger C, Ryan RJ, Iwamoto Y, Marinelli B, Gorbatov R, Forghani R, Novobrantseva TI, Koteliansky V, Figueiredo JL, Chen JW, Anderson DG, Nahrendorf M, Swirski FK, Weissleder R, Pittet MJ. 2012. Origins of tumor-associated macrophages and neutrophils. PNAS 109:2491-2496. doi: 10.1073/pnas.1113744109
14. Cripps JG, Gorham JD. 2011. MDSC in autoimmunity. International Immunopharmacology 11:789-793. doi: 10.1016/j.intimp.2011.01.026
15. Crook KR, Jin M, Weeks MF, Rampersad RR, Baldi RM, Glekas AS, Shen Y, Esserman DA, Little P, Schwartz TA, Liu P. 2015. Myeloid-derived suppressor cells regulate T cell and B cell responses during autoimmune disease. Journal of Leukocyte Biology 97:573-582. doi: 10.1189/jlb.4A0314-139R
16. Crook KR, Liu P. 2014. Role of myeloid-derived suppressor cells in autoimmune disease. World Journal of Immunology 4:26-33. doi: 10.5411/wji.v4.i1.26
17. Evans SS, Repasky EA, Fisher DT. 2015. Fever and the thermal regulation of immunity: the immune system feels the heat. Nature Reviews Immunology 15:335-349. doi: 10.1038/nri3843
18. Feehan C, Darlak K, Kahn J, Walcheck B, Spatola AF, Kishimoto TK. 1996. Shedding of the lymphocyte L-selectin adhesion molecule is inhibited by a hydroxamic acid-based protease inhibitor. identification with an L-selectin-alkaline phosphatase reporter. The Journal of Biological Chemistry 271:7019-7024. doi: 10.1074/jbc.271.12.7019
19. Fisher DT, Chen Q, Skitzki JJ, Muhitch JB, Zhou L, Appenheimer MM, Vardam TD, Weis EL, Passanese J, Wang WC, Gollnick SO, Dewhirst MW, Rose-John S, Repasky EA, Baumann H, Evans SS. 2011. IL-6 trans-signaling licenses mouse and human tumor microvascular gateways for trafficking of cytotoxic T cells. Journal of Clinical Investigation 121:3846-3859. doi: 10.1172/JCI44952
20. Ford WL. 1979. Lymphocytes. 3. Distribution. distribution of lymphocytes in health. Journal of Clinical Pathology 13:63-69. doi: 10.1136/jcp.s3-13.1.63
21. Gabrilovich DI, Ostrand-Rosenberg S, Bronte V. 2012. Coordinated regulation of myeloid cells by tumours. Nature Reviews Immunology 12:253-268. doi: 10.1038/nri3175
22. Galkina E, Thatte J, Dabak V, Williams MB, Ley K, Braciale TJ. 2005. Preferential migration of effector CD8+ T cells into the interstitium of the normal lung. Journal of Clinical Investigation 115:3473-3483. doi: 10.1172/JCI24482
23. Garcia AJ, Ruscetti M, Arenzana TL, Tran LM, Bianci-Frias D, Sybert E, Priceman SJ, Wu L, Nelson PS, Smale ST, Wu H. 2014. Pten null prostate epithelium promotes localized myeloid-derived suppressor cell expansion and immune suppression during tumor initiation and progression. Molecular and Cellular Biology 34:2017-2028. doi: 10.1128/MCB.00090-14
24. Gattinoni L, Klebanoff CA, Palmer DC, Wrzesinski C, Kerstann K, Yu Z, Finkelstein SE, Theoret MR, Rosenberg SA, Restifo NP. 2005. Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells. Journal of Clinical Investigation 115:1616-1626. doi: 10.1172/JCI24480
25. Gattinoni L, Lugli E, Ji Y, Pos Z, Paulos CM, Quigley MF, Almeida JR, Gostick E, Yu Z, Carpenito C, Wang E, Douek DC, Price DA, June CH, Marincola FM, Roederer M, Restifo NP. 2011. A human memory T cell subset with stem cell-like properties. Nature Medicine 17:1290-1297. doi: 10.1038/nm.2446
26. Gauguet JM, Rosen SD, Marth JD, von Andrian UH. 2004. Core 2 branching beta1,6-N-acetylglucosaminyltransferase and high endothelial cell N-acetylglucosamine-6-sulfotransferase exert differential control over B- and T-lymphocyte homing to peripheral lymph nodes. Blood 104:4104-4112. doi: 10.1182/blood-2004-05-1986
27. Girard JP, Moussion C, Forster R. 2012. HEVs, lymphatics and homeostatic immune cell trafficking in lymph nodes. Nature Reviews Immunology 12:762-773. doi: 10.1038/nri3298
28. Goh C, Narayanan S, Hahn YS. 2013. Myeloid-derived suppressor cells: the dark knight or the joker in viral infections? Immunological Reviews 255:210-221. doi: 10.1111/imr.12084
29. Grailer JJ, Kodera M, Steeber DA. 2009. L-selectin: role in regulating homeostasis and cutaneous inflammation. Journal of Dermatological Science 56:141-147. doi: 10.1016/j.jdermsci.2009.10.001
30. Guy CT, Cardiff RD, Muller WJ. 1992. Induction of mammary tumors by expression of polyomavirus middle T oncogene: a transgenic mouse model for metastatic disease. Molecular and Cellular Biology 12:954-961. doi: 10.1128/MCB.12.3.954
31. Hanson EM, Clements VK, Sinha P, Ilkovitch D, Ostrand-Rosenberg S. 2009. Myeloid-derived suppressor cells down-regulate L-selectin expression on CD4+ and CD8+ T cells. The Journal of Immunology 183:937-944. doi: 10.4049/jimmunol.0804253
32. Huang B, Pan PY, Li Q, Sato AI, Levy DE, Bromberg J, Divino CM, Chen SH. 2006. Gr-1+CD115+ immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host. Cancer Research 66:1123-1131. doi: 10.1158/0008-5472.CAN-05-1299
33. Isobe K, Nakashima I. 1991. Homotypic aggregation of murine T lymphocytes induced by anti-Thy-1 monoclonal antibodies. Immunology 73:159-164
34. Issekutz TB, Chin W, Hay JB. 1982. The characterization of lymphocytes migrating through chronically inflamed tissues. Immunology 46:59-66
35. Ito F, Ku AW, Bucsek MJ, Muhitch JB, Vardam-Kaur T, Kim M, Fisher DT, Camoriano M, Khoury T, Skitzki JJ, Gollnick SO, Evans SS. 2015. Immune adjuvant activity of Pre-Resectional radiofrequency ablation protects against local and systemic recurrence in aggressive murine colorectal cancer. PLoS One 10:e0143370. doi: 10.1371/journal.pone.0143370
36. Jasuja RR, Mier JW. 2000. Differential effects of hydroxamate inhibitors on PMA and ligand-induced L-Selectin down-modulation: role of membrane proximal and cytoplasmic domains. International Journal of Immunopathology and Pharmacology 13:1-12
37. Jenkins MK, Chu HH, McLachlan JB, Moon JJ. 2010. On the composition of the preimmune repertoire of T cells specific for Peptide-major histocompatibility complex ligands. Annual Review of Immunology 28:275-294. doi: 10.1146/annurev-immunol-030409-101253
38. Jiang Y, Li Y, Zhu B. 2015. T-cell exhaustion in the tumor microenvironment. Cell Death and Disease 6:e1792. doi: 10.1038/cddis.2015.162
39. Kerdiles YM, Beisner DR, Tinoco R, Dejean AS, Castrillon DH, DePinho RA, Hedrick SM. 2009. Foxo1 links homing and survival of naive T cells by regulating L-selectin, CCR7 and interleukin 7 receptor. Nature Immunology 10:176-184. doi: 10.1038/ni.1689
40. Kimura T, McKolanis JR, Dzubinski LA, Islam K, Potter DM, Salazar AM, Schoen RE, Finn OJ. 2013. MUC1 vaccine for individuals with advanced adenoma of the colon: a cancer immunoprevention feasibility study. Cancer Prevention Research 6:18-26. doi: 10.1158/1940-6207.CAPR-12-0275
41. Kishimoto TK, Jutila MA, Berg EL, Butcher EC. 1989. Neutrophil Mac-1 and MEL-14 adhesion proteins inversely regulated by chemotactic factors. Science 245:1238-1241. doi: 10.1126/science.2551036
42. Kobawala TP, Trivedi TI, Gajjar KK, Patel DH, Patel GH, Ghosh NR. 2016. Significance of TNF-alpha and the adhesion molecules: L-Selectin and VCAM-1 in Papillary Thyroid Carcinoma. Journal of Thyroid Research 2016: 8143695. doi: 10.1155/2016/8143695
43. Krebs MG, Metcalf RL, Carter L, Brady G, Blackhall FH, Dive C. 2014. Molecular analysis of circulating tumour cells-biology and biomarkers. Nature Reviews Clinical Oncology 11:129-144. doi: 10.1038/nrclinonc.2013.253
44. Levy L, Mishalian I, Bayuch R, Zolotarov L, Michaeli J, Fridlender ZG. 2015. Splenectomy inhibits non-small cell lung cancer growth by modulating anti-tumor adaptive and innate immune response. OncoImmunology 4: e998469. doi: 10.1080/2162402X.2014.998469
45. Li Y, Brazzell J, Herrera A, Walcheck B. 2006. ADAM17 deficiency by mature neutrophils has differential effects on L-selectin shedding. Blood 108:2275-2279. doi: 10.1182/blood-2006-02-005827
46. Liu CY, Wang YM, Wang CL, Feng PH, Ko HW, Liu YH, Wu YC, Chu Y, Chung FT, Kuo CH, Lee KY, Lin SM, Lin HC, Wang CH, Yu CT, Kuo HP. 2010. Population alterations of L-arginase-and inducible nitric oxide synthase-expressed CD11b+/CD14 /CD15+/CD33+ myeloid-derived suppressor cells and CD8+ T lymphocytes in patients with advanced-stage non-small cell lung cancer. Journal of Cancer Research and Clinical Oncology 136:35-45. doi: 10.1007/s00432-009-0634-0
47. M’Rini C, Cheng G, Schweitzer C, Cavanagh LL, Palframan RT, Mempel TR, Warnock RA, Lowe JB, Quackenbush EJ, von Andrian UH. 2003. A novel endothelial L-selectin ligand activity in lymph node medulla that is regulated by alpha(1,3)-fucosyltransferase-IV. The Journal of Experimental Medicine 198:1301-1312. doi: 10.1084/jem.20030182
48. McGowan PM, Mullooly M, Caiazza F, Sukor S, Madden SF, Maguire AA, Pierce A, McDermott EW, Crown J, O’Donovan N, Duffy MJ. 2013. ADAM-17: a novel therapeutic target for triple negative breast cancer. Annals of Oncology 24:362-369. doi: 10.1093/annonc/mds279
49. Mikucki ME, Fisher DT, Matsuzaki J, Skitzki JJ, Gaulin NB, Muhitch JB, Ku AW, Frelinger JG, Odunsi K, Gajewski TF, Luster AD, Evans SS. 2015. Non-redundant requirement for CXCR3 signalling during tumoricidal T-cell trafficking across tumour vascular checkpoints. Nature Communications 6:7458. doi: 10.1038/ncomms8458
50. Mishra HK, Johnson TJ, Seelig DM, Walcheck B. 2016. Targeting ADAM17 in leukocytes increases neutrophil recruitment and reduces bacterial spread during polymicrobial sepsis. Journal of Leukocyte Biology 100:999-1004. doi: 10.1189/jlb.3VMAB1115-496RR
51. Morrison VL, Barr TA, Brown S, Gray D. 2010. TLR-mediated loss of CD62L focuses B cell traffic to the spleen during salmonella typhimurium infection. The Journal of Immunology 185:2737-2746. doi: 10.4049/jimmunol.1000758
52. Mundy-Bosse BL, Lesinski GB, Jaime-Ramirez AC, Benninger K, Khan M, Kuppusamy P, Guenterberg K, Kondadasula SV, Chaudhury AR, La Perle KM, Kreiner M, Young G, Guttridge DC, Carson WE. 2011. Myeloid-derived suppressor cell inhibition of the IFN response in tumor-bearing mice. Cancer Research 71:5101-5110. doi: 10.1158/0008-5472.CAN-10-2670
53. Munn DH, Sharma MD, Hou D, Baban B, Lee JR, Antonia SJ, Messina JL, Chandler P, Koni PA, Mellor AL. 2004. Expression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes. Journal of Clinical Investigation 114:280-290. doi: 10.1172/JCI200421583
54. Oh K, Lee OY, Shon SY, Nam O, Ryu PM, Seo MW, Lee DS. 2013. A mutual activation loop between breast cancer cells and myeloid-derived suppressor cells facilitates spontaneous metastasis through IL-6 trans-signaling in a murine model. Breast Cancer Research 15:R79. doi: 10.1186/bcr3473
55. Oshiba A, Renz H, Yata J, Gelfand EW. 1994. Isolation and characterization of human antigen-specific B lymphocytes. Clinical Immunology and Immunopathology 72:342-349. doi: 10.1006/clin.1994.1151
56. Ostrand-Rosenberg S, Sinha P, Beury DW, Clements VK. 2012. Cross-talk between myeloid-derived suppressor cells (MDSC), macrophages, and dendritic cells enhances tumor-induced immune suppression. Seminars in Cancer Biology 22:275-281. doi: 10.1016/j.semcancer.2012.01.011
57. Ostrand-Rosenberg S, Sinha P. 2009. Myeloid-derived suppressor cells: linking inflammation and cancer. The Journal of Immunology 182:4499-4506 doi: 10.4049/jimmunol.0802740
58. Parker KH, Sinha P, Horn LA, Clements VK, Yang H, Li J, Tracey KJ, Ostrand-Rosenberg S. 2014. HMGB1 enhances immune suppression by facilitating the differentiation and suppressive activity of myeloid-derived suppressor cells. Cancer Research 74:5723-5733. doi: 10.1158/0008-5472.CAN-13-2347, PMID: 25164013
59. Preece G, Murphy G, Ager A. 1996. Metalloproteinase-mediated regulation of L-selectin levels on leucocytes. Journal of Biological Chemistry 271:11634-11640. doi: 10.1074/jbc.271.20.11634
60. Rzeniewicz K, Newe A, Rey Gallardo A, Davies J, Holt MR, Patel A, Charras GT, Stramer B, Molenaar C, Tedder TF, Parsons M, Ivetic A. 2015. L-selectin shedding is activated specifically within transmigrating pseudopods of monocytes to regulate cell polarity in vitro. PNAS 112:E1461-1470. doi: 10.1073/pnas.1417100112
61. Shao JY, Hochmuth RM. 1999. Mechanical anchoring strength of L-selectin, beta2 integrins, and CD45 to neutrophil cytoskeleton and membrane. Biophysical Journal 77:587-596. doi: 10.1016/S0006-3495(99)76915-8
62. Simon SI, Chambers JD, Butcher E, Sklar LA. 1992. Neutrophil aggregation is beta 2-integrin- and L-selectin-dependent in blood and isolated cells. Journal of Immunology 149:2765-2771
63. Sinha P, Clements VK, Bunt SK, Albelda SM, Ostrand-Rosenberg S. 2007. Cross-talk between myeloid-derived suppressor cells and macrophages subverts tumor immunity toward a type 2 response. The Journal of Immunology 179:977-983. doi: 10.4049/jimmunol.179.2.977
64. Stein JV, Rot A, Luo Y, Narasimhaswamy M, Nakano H, Gunn MD, Matsuzawa A, Quackenbush EJ, Dorf ME, von Andrian UH. 2000. The CC chemokine thymus-derived chemotactic agent 4 (TCA-4, secondary lymphoid tissue chemokine, 6Ckine, exodus-2) triggers lymphocyte function-associated antigen 1-mediated arrest of rolling T lymphocytes in peripheral lymph node high endothelial venules. The Journal of Experimental Medicine 191:61-76. doi: 10.1084/jem.191.1.61
65. Stewart TJ, Liewehr DJ, Steinberg SM, Greeneltch KM, Abrams SI. 2009. Modulating the expression of IFN regulatory factor 8 alters the protumorigenic behavior of CD11b+Gr-1+ myeloid cells. The Journal of Immunology 183:117-128. doi: 10.4049/jimmunol.0804132
66. Stoddart JH, Jasuja RR, Sikorski MA, von Andrian UH, Mier JW. 1996. Protease-resistant L-selectin mutants. Down-modulation by cross-linking but not cellular activation. Journal of Immunology 157:5653-5659
67. Takahama Y. 2006. Journey through the thymus: stromal guides for T-cell development and selection. Nature Reviews Immunology 6:127-135. doi: 10.1038/nri1781
68. Talmadge JE, Gabrilovich DI. 2013. History of myeloid-derived suppressor cells. Nature Reviews Cancer 13:739-752. doi: 10.1038/nrc3581
69. Tang ML, Steeber DA, Zhang XQ, Tedder TF. 1998. Intrinsic differences in L-selectin expression levels affect T and B lymphocyte subset-specific recirculation pathways. Journal of Immunology 160:5113-5121
70. Tario JD, Muirhead KA, Pan D, Munson ME, Wallace PK, Jr. KA, Pan MEM. 2011. Tracking immune cell proliferation and cytotoxic potential using flow cytometry. Methods in Molecular Biology 699:119-164. doi: 10.1007/978-1-61737-950-5_7
71. Trellakis S, Bruderek K, Hutte J, Elian M, Hoffmann TK, Lang S, Brandau S. 2013. Granulocytic myeloid-derived suppressor cells are cryosensitive and their frequency does not correlate with serum concentrations of colony-stimulating factors in head and neck cancer. Innate Immunity 19:328-336. doi: 10.1177/1753425912463618
72. Tu L, Poe JC, Kadono T, Venturi GM, Bullard DC, Tedder TF, Steeber DA. 2002. A functional role for circulating mouse L-selectin in regulating leukocyte/endothelial cell interactions in vivo. The Journal of Immunology 169: 2034-2043. doi: 10.4049/jimmunol.169.4.2034
73. Ugel S, Peranzoni E, Desantis G, Chioda M, Walter S, Weinschenk T, Ochando JC, Cabrelle A, Mandruzzato S, Bronte V. 2012. Immune tolerance to tumor antigens occurs in a specialized environment of the spleen. Cell Reports 2:628-639. doi: 10.1016/j.celrep.2012.08.006
74. Venturi GM, Tu L, Kadono T, Khan AI, Fujimoto Y, Oshel P, Bock CB, Miller AS, Albrecht RM, Kubes P, Steeber DA, Tedder TF. 2003. Leukocyte migration is regulated by L-selectin endoproteolytic release. Immunity 19: 713-724. doi: 10.1016/S1074-7613(03)00295-4
75. Vincent J, Mignot G, Chalmin F, Ladoire S, Bruchard M, Chevriaux A, Martin F, Apetoh L, Rébé C, Ghiringhelli F. 2010.5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity. Cancer Research 70:3052-3061. doi: 10.1158/0008-5472.CAN-09-3690
76. Waight JD, Hu Q, Miller A, Liu S, Abrams SI. 2011. Tumor-derived G-CSF facilitates neoplastic growth through a granulocytic myeloid-derived suppressor cell-dependent mechanism. PLoS One 6:e27690. doi: 10.1371/journal.pone.0027690
77. Waight JD, Netherby C, Hensen ML, Miller A, Hu Q, Liu S, Bogner PN, Farren MR, Lee KP, Liu K, Abrams SI. 2013. Myeloid-derived suppressor cell development is regulated by a STAT/IRF-8 axis. Journal of Clinical Investigation 123:4464-4478. doi: 10.1172/JCI68189
78. Walcheck B, Alexander SR, St Hill CA, Matala E. 2003. ADAM-17-independent shedding of L-selectin. Journal of Leukocyte Biology 74:389-394. doi: 10.1189/jlb.0403141
79. Wang Y, Wu J, Newton R, Bahaie NS, Long C, Walcheck B. 2013. ADAM17 cleaves CD16b (FcgRIIIb) in human neutrophils. Biochimica et Biophysica Acta (BBA) - Molecular Cell Research 1833:680-685. doi: 10.1016/j.bbamcr.2012.11.027
80. Witters L, Scherle P, Friedman S, Fridman J, Caulder E, Newton R, Lipton A. 2008. Synergistic inhibition with a dual epidermal growth factor receptor/HER-2/neu tyrosine kinase inhibitor and a disintegrin and metalloprotease inhibitor. Cancer Research 68:7083-7089. doi: 10.1158/0008-5472.CAN-08-0739
81. Xu J, Escamilla J, Mok S, David J, Priceman S, West B, Bollag G, McBride W, Wu L. 2013. CSF1R signaling blockade stanches tumor-infiltrating myeloid cells and improves the efficacy of radiotherapy in prostate cancer. Cancer Research 73:2782-2794. doi: 10.1158/0008-5472.CAN-12-3981
82. Yang S, Liu F, Wang QJ, Rosenberg SA, Morgan RA. 2011. The shedding of CD62L (L-selectin) regulates the acquisition of lytic activity in human tumor reactive T lymphocytes. PLoS One 6:e22560. doi: 10.1371/journal.pone.0022560
83. Youn JI, Nagaraj S, Collazo M, Gabrilovich DI. 2008. Subsets of myeloid-derived suppressor cells in tumor-bearing mice. The Journal of Immunology 181:5791-5802. doi: 10.4049/jimmunol.181.8.5791
84. Zhao X, Rong L, Zhao X, Li X, Liu X, Deng J, Wu H, Xu X, Erben U, Wu P, Syrbe U, Sieper J, Qin Z. 2012. TNF signaling drives myeloid-derived suppressor cell accumulation. Journal of Clinical Investigation 122:4094-4104. doi: 10.1172/JCI64115